Hennion & Walsh Asset Management Inc. increased its position in Geron Co. (NASDAQ:GERN – Free Report) by 34.7% during the third quarter, HoldingsChannel.com reports. The firm owned 341,884 shares of the biopharmaceutical company’s stock after acquiring an additional 88,027 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Geron were worth $1,552,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of GERN. Darwin Global Management Ltd. purchased a new position in Geron in the second quarter worth about $106,185,000. Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of Geron during the first quarter valued at approximately $333,000. Renaissance Technologies LLC purchased a new position in Geron in the 2nd quarter worth approximately $3,315,000. Price T Rowe Associates Inc. MD lifted its position in Geron by 999.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock valued at $6,815,000 after acquiring an additional 1,877,184 shares in the last quarter. Finally, Algert Global LLC purchased a new stake in Geron during the 2nd quarter valued at $539,000. Institutional investors own 73.71% of the company’s stock.
Geron Stock Up 1.5 %
Shares of GERN stock opened at $4.06 on Friday. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12. Geron Co. has a 12 month low of $1.64 and a 12 month high of $5.34. The stock has a market cap of $2.45 billion, a P/E ratio of -11.28 and a beta of 0.50. The company has a 50 day simple moving average of $4.38 and a two-hundred day simple moving average of $4.27.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. StockNews.com upgraded Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partners initiated coverage on Geron in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price for the company. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a report on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Geron in a report on Friday, August 9th. Finally, Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Geron presently has a consensus rating of “Moderate Buy” and an average target price of $6.94.
Read Our Latest Research Report on Geron
Geron Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Stories
- Five stocks we like better than Geron
- What is a Bond Market Holiday? How to Invest and Trade
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a Low P/E Ratio and What Does it Tell Investors?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is MarketRank™? How to Use it
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN – Free Report).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.